Mostrando 10 resultados de: 32
Filtros aplicados
4th ESPT Conference: Pharmacogenomics and personalized medicine - Research progress and clinical implementation
ArticleAbstract: The Fourth European Society of Pharmacogenomics and Personalized Therapy biennial conference was orgPalabras claves:clinical implementation, ESPT conference, personalized medicine, PharmacogenomicsAutores:Adrián LLerena, Ansari M., Cascorbi I., Drago F., Gozzo L., Ingelman-Sundberg M., Katsila T., Manolopoulos V.G., Marc J., Marchetti P., Meyer U.A., Mlakar V., Nofziger C., Paulmichl M., Pearson E., Re M.D., Simmaco M., Sipeky C., Stanković S., Suarez-Kurtz G., Van Schaik R.H.N.Fuentes:scopus4th ESPT summer school: Precision medicine and personalised health
Conference ObjectAbstract: In September 2018, the European Society of Pharmacogenomics and Personalised Therapy (ESPT), with thPalabras claves:Autores:Adrián LLerena, Amstutz U., Ansari M., Cascorbi I., Manolopoulos V.G., Marc J., Meier-Abt P., Meyer U.A., Mlakar V., Simmaco M., Sipeky C., Stanković S., Van Schaik R.H.N., Visvikis-Siest S.Fuentes:scopusDevelopment of a new genotyping assay for detection of the BDNF Val66Met polymorphism using melting-curve analysis
ArticleAbstract: Brain-derived neurotrophic factor (BDNF) plays critical role in the growth, differentation and surviPalabras claves:BDNF, Melting curve, Schizophrenia patients, SYBR, Val66Met polymorphismAutores:Adrián LLerena, Dorado P., Guarino E., Sánchez-Romero M.A.Fuentes:scopusCYP2D6 and the severity of suicide attempts
ArticleAbstract: Aim: Among people who die by suicide, an increased frequency of CYP2D6 active gene multiplication haPalabras claves:CYP2D6, severity of suicide attempt, ultrarapid metabolizerAutores:Adrián LLerena, Baca-Garca E., Blasco-Fontecilla H., Dorado P., Penãs-Lledó E.M., Vaquero-Lorenzo C.Fuentes:scopusCYP2D6 gene polymorphisms and pbkp_redicted phenotypes in eight indigenous groups from northwestern Mexico
ArticleAbstract: Aim: Polymorphisms in CYP2D6 impact the interindividual and interethnic variability of drug efficienPalabras claves:allele frequency, CYP2D6polymorphism, Mexican indigenous, pbkp_redicted phenotype, pharmacogeneticsAutores:Adrián LLerena, Galaviz-Hernandez C., Garza-Veloz I., Lazalde-Ramos B.P., Martínez-Fierro M.L., Naranjo M.E.G., Sosa-Macías M.G.Fuentes:scopusCYP2D6 genetic polymorphisms in Southern Mexican Mayan Lacandones and Mestizos from Chiapas
ArticleAbstract: Aim: In previous CYP2D6 genotyping studies in Mexican-Amerindians a very low frequency of poor metabPalabras claves:CYP2D6, Lacandones, Mexican-Mestizo, pharmacogeneticsAutores:Adrián LLerena, Alonso E., Dorado P., López-López M., Ochoa-Morales A., Ortega A., Penãs-Lledó E.M., Vázquez T.C., Yescas-Gómez P.Fuentes:scopusCYP2D6 genotyping for psychiatric patients treated with risperidone: Considerations for cost-effectiveness studies
ArticleAbstract: In order to ascertain data availability and feasibility for conducting cost-effectiveness studies inPalabras claves:adverse drug reactions, Antipsychotic, cost-effectiveness, CYP2D6, polymorphisms, RisperidoneAutores:Adrián LLerena, De Leon J., de Mesa E.G., Gurwitz D., Ibarreta D., Kirchheiner J., Rodríguez-Antona C.Fuentes:scopusCYP2D6 polymorphism: Implications for antipsychotic drug response, schizophrenia and personality traits
ReviewAbstract: The CYP2D6 gene is highly polymorphic, causing absent (poor metabolizers), decreased, normal or incrPalabras claves:Adverse side effects, antipsychotics, CYP2D6, personality, pharmacogenetics, Pharmacogenomics, QTc, Schizophrenia, vulnerabilityAutores:Adrián LLerena, Dorado P., Penãs-Lledó E.M.Fuentes:scopusCYP2D6-1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers
ArticleAbstract: Background & aim: The CYP2D6-1584C>G polymorphism (rs1080985) has been identified as a major factorPalabras claves:1584C>G, CYP2D6, debrisoquine, Healthy volunteers, ultrarapid metabolismAutores:Adrián LLerena, Alvárez M., Calzadilla L.R., Dorado P., González I., Naranjo M.E.G., Penãs-Lledó E.M., Pérez B., Ramirez R.Fuentes:scopusCYP450 genotype and pharmacogenetic association studies: A critical appraisal
ReviewAbstract: Despite strong pharmacological support, association studies using genotype-pbkp_redicted phenotype aPalabras claves:drug metabolizing enzymes, ethnicity, Genotype, pharmacogenetic association studies, pharmacogenetics, phenoconversion, Phenotype, substrate-selectivity, Therapeutic drug monitoringAutores:Adrián LLerena, Eichelbaum M., Gaedigk A., Shah R.R., Smith R.L., Stingl J.C.Fuentes:scopus